1035 related articles for article (PubMed ID: 9247771)
21. [Treatment of renal anemia with iron in hemodialysis patients in General Hospital Bjelovar].
Lovcić V; Vujić J; Basić-Jukić N; Janković RI; Kurtović I; Dzapo M; Lovcić P
Acta Med Croatica; 2011 Oct; 65 Suppl 3():45-8. PubMed ID: 23120815
[TBL] [Abstract][Full Text] [Related]
22. [Stability of hemoglobin levels: an indispensible paradigm change in medical management].
Zaoui P; Deray G; Ortiz JP; Rostaing L
Nephrol Ther; 2011 Feb; 7(1 Suppl 2):H5-7. PubMed ID: 21371678
[No Abstract] [Full Text] [Related]
23. Intravenous iron, inflammation, and oxidative stress: is iron a friend or an enemy of uremic patients?
Garneata L
J Ren Nutr; 2008 Jan; 18(1):40-5. PubMed ID: 18089442
[TBL] [Abstract][Full Text] [Related]
24. Impact of inflammation on nutrition, iron status, and erythropoietin responsiveness in ESRD patients.
Bistrian BR; Carey LA
Nephrol Nurs J; 2000 Dec; 27(6):616-22. PubMed ID: 16649343
[TBL] [Abstract][Full Text] [Related]
25. Clinical efficacy of recombinant human erythropoietin in hemodialysis patients.
Mohini R
Semin Nephrol; 1989 Mar; 9(1 Suppl 1):16-21. PubMed ID: 2648516
[TBL] [Abstract][Full Text] [Related]
26. Iron overload in the erythropoietin era.
Robbins KC
Nephrol Nurs J; 2000 Apr; 27(2):227-31. PubMed ID: 11111550
[TBL] [Abstract][Full Text] [Related]
27. [Erythropoietin-beta in the treatment of anemia in patients with chronic renal insufficiency].
Dimković N
Med Pregl; 2001; 54(5-6):235-40. PubMed ID: 11759218
[TBL] [Abstract][Full Text] [Related]
28. [Treatment of anemia with recombinant human erythropoietin and the bone marrow response in uremic patients undergoing periodic hemodialysis].
García Martín F; Carrascosa Vallejo T; Martín Escobar E; Val Begueria J; Martín Hernández R; de Arriba G; Teno C; Salvatierra J
Rev Clin Esp; 1990 May; 186(9):419-22. PubMed ID: 2247677
[TBL] [Abstract][Full Text] [Related]
29. Iron requirements in hemodialysis.
Sargent JA; Acchiardo SR
Blood Purif; 2004; 22(1):112-23. PubMed ID: 14732819
[TBL] [Abstract][Full Text] [Related]
30. Effect of recombinant human erythropoietin on iron balance in maintenance hemodialysis: theoretical considerations, clinical experience and consequences.
Grützmacher P; Tsobanelis T; Roth P; Werner E; Vlachojannis J; Kaltwasser J; Kurz P; Scheuermann EH; Schoeppe W
Clin Nephrol; 1992; 38 Suppl 1():S92-7. PubMed ID: 1295714
[TBL] [Abstract][Full Text] [Related]
31. [Tumor anemia. Overview of the role of human recombinant erythropoietin (r-hu-EPO) in treatment of tumor anemia].
Monnerat C; Leyvraz S
Praxis (Bern 1994); 1999 Jan; 88(5):178-88. PubMed ID: 10067375
[TBL] [Abstract][Full Text] [Related]
32. The use of recombinant human erythropoietin (EPO) to correct the anemia of end-stage renal disease: a progress report.
Adamson W; Egrie JC; Browne JK; Downing MR; Eschbach W
Behring Inst Mitt; 1988 Aug; (83):188-92. PubMed ID: 3071336
[TBL] [Abstract][Full Text] [Related]
33. The efficiency of fractionated parenteral iron treatment in CAPD patients.
Akcicek F; Ozkahya M; Cirit M; Ok E; Unsal A; Toz H; Celik A; Atabay G; Basci A
Adv Perit Dial; 1997; 13():109-12. PubMed ID: 9360661
[TBL] [Abstract][Full Text] [Related]
34. Intravenous iron sucrose in Chinese hemodialysis patients with renal anemia.
Li H; Wang SX
Blood Purif; 2008; 26(2):151-6. PubMed ID: 18212498
[TBL] [Abstract][Full Text] [Related]
35. [Anemia syndrome in patients with chronic renal insufficiency on peritoneal dialysis treated with recombinant erythropoietin].
Romanova LA; Lugovskaia SA; Khareb F; Shumov EV; Shmarov DA
Urologiia; 2002; (5):26-30. PubMed ID: 12402772
[TBL] [Abstract][Full Text] [Related]
36. Intravenous iron in chronic kidney disease: haemoglobin change shortly after treatment of patients neither on dialysis nor on erythropoietin.
Tagboto S; Cropper L; Mostafa S; Turner J; Bailey G; Pugh-Clarke K
J Ren Care; 2008 Sep; 34(3):112-5. PubMed ID: 18786076
[TBL] [Abstract][Full Text] [Related]
37. The clinical effects of recombinant human erythropoietin for the treatment of anemia in end stage renal disease patients on dialysis.
Uthayanaka Y; Jirajan B; Krairithichai U; Jantavanich N
Southeast Asian J Trop Med Public Health; 1993 Sep; 24(3):577-82. PubMed ID: 8160072
[TBL] [Abstract][Full Text] [Related]
38. Optimal treatment of renal anaemia (OPTA): improving the efficacy and efficiency of renal anaemia therapy in haemodialysis patients receiving intravenous epoetin.
Hörl WH; Vanrenterghem Y; Canaud B; Mann J; Teatini U; Wanner C; Wikström B
Nephrol Dial Transplant; 2005 May; 20 Suppl 3():iii25-32. PubMed ID: 15824127
[TBL] [Abstract][Full Text] [Related]
39. Guidelines for recombinant human erythropoietin therapy.
Eschbach JW; Adamson JW
Am J Kidney Dis; 1989 Aug; 14(2 Suppl 1):2-8. PubMed ID: 2667349
[TBL] [Abstract][Full Text] [Related]
40. Comparative response to single or divided doses of parenteral iron for functional iron deficiency in hemodialysis patients receiving erythropoietin (EPO).
Saltissi D; Sauvage D; Westhuyzen J
Clin Nephrol; 1998 Jan; 49(1):45-8. PubMed ID: 9491286
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
